Opus Genetics, Inc. Form 8-K Summary
Business Context and Reporting Period
Opus Genetics, Inc. (Nasdaq: IRD), a Delaware corporation, filed this Current Report on Form 8-K on April 2, 2026. The filing discloses the entry into material definitive agreements to secure financing and issue equity securities to support its operations and development pipeline, specifically referencing its product candidate OPGx-LCA5.
Key Financial Metrics and Transaction Details
The filing details a significant capital raise structured through debt and equity instruments:
- Debt Financing: Entered into a Note Purchase Agreement for up to $155 million in senior secured notes.
- Committed Amount: $105 million.
- Uncommitted Amount: $50 million (subject to purchaser discretion).
- Initial Funding: $35 million tranche expected to close on April 20, 2026.
- Interest Rate: Term SOFR (3-month) plus an Applicable Margin, subject to a 3.68% floor.
- Interest Payment Structure: 50% paid in kind (PIK) and 50% in cash for the first eight interest periods; 100% cash thereafter.
- Maturity: April 2, 2033, with a mandatory principal payment of 50% of the outstanding balance on the sixth anniversary of the first purchase date.
- Equity Financing: Entered into a Stock Purchase and Conversion Agreement.
- Shares Issued: 1,116,070 shares of Common Stock.
- Purchase Price: $4.48 per share.
- Total Proceeds: Approximately $5.0 million ($4,999,994).
- Conversion Feature: Note holders may convert up to 10% of their principal into common stock at a fixed price of $6.72 per share within 18 months of the effective date.
Material Changes and Milestone Tranches
The debt facility includes milestone-based tranches that alter the capital structure based on regulatory progress:
- Second Tranche: $35 million available at the Company's option until April 2, 2027.
- Third Tranche: $25 million funded upon FDA Application Acceptance for OPGx-LCA5 on or before March 31, 2028.
- Fourth Tranche: $10 million available upon FDA Approval of OPGx-LCA5 or at the Purchaser Agent's option if the Third Tranche is not funded by March 31, 2028.
- Uncommitted Tranches: Two additional $25 million tranches available until December 31, 2027, subject to purchaser approval.
The equity agreement includes a "Dilutive Equity Round" provision allowing purchasers to acquire additional shares at $0.0001 per share if the Company issues equity below $4.48 per share prior to October 2, 2026, to maintain a weighted average price.
Guidance, Risks, and Covenants
Covenants and Security: The Notes are secured by a pledge of all equity interests of subsidiaries and a security interest in substantially all tangible and intangible assets. The agreement includes customary negative covenants restricting indebtedness, liens, mergers, and dividends.
Prepayment and Default: The Company may voluntarily prepay notes subject to a premium. Mandatory prepayments are required from insurance proceeds or condemnation awards. Events of default allow for acceleration of obligations.
Registration Rights: The Company must file a shelf registration statement within 30 days to register the resale of the Purchase Shares and Conversion Shares.
Risks: The filing includes standard forward-looking statement disclaimers regarding the consummation of the private placement, market conditions, and the satisfaction of closing conditions. Actual results may differ materially from expectations.
Investor Verification Checklist
- Verify the exact "Applicable Margin" added to the Term SOFR rate, as the specific percentage is not defined in the summary text.
- Confirm the closing date of the initial $35 million tranche and the $5 million equity issuance (expected April 20, 2026).
- Review the full Note Purchase Agreement (Exhibit 10.1) for specific definitions of "customary permitted liens" and exceptions to mandatory prepayments.
- Monitor the status of the FDA Application Acceptance for OPGx-LCA5, which triggers the $25 million third tranche.
- Check for any subsequent filings regarding the effectiveness of the shelf registration statement required within 30 days of April 2, 2026.